EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML

Yuichiro Semba, Toshihiro Miyamoto iD, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima iD, Hiroki Hosoi, Daigo Niiya, Koji Kato iD und 10 weitere

Cancer Science · 2026-11 · 117 (11) · 3108-3120

DOI: 10.1111/cas.70485 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, online erschienen am 12.08.2026. Verfasst von Yuichiro Semba und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Phenylurea Compounds, Drug Resistance, Neoplasm. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication ( FLT3 ‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3 ‐ITD–positive AML. This multicenter, single‐arm study in Japan (jRCTs071200015) enrolled 18 patients between May 2020 and December 2022. Of these, 15 patients received oral quizartinib (up to 53 mg once daily) for up to 12 cycles of 28 days each, then were followed for 12 months. The primary endpoint was to evaluate the type and rate of quizartinib resistance mutations; secondary endpoints included composite complete remission (CRc) rate, overall response rate (ORR), hematopoietic stem cell transplantation (HSCT) rate, relapse‐free survival (RFS), overall survival (OS), and adverse events (AEs). Among seven evaluable patients, acquired mutations were detected in four patients ( NF1 [R2616X], CSF3R [Q754X], NRAS [G13R], and FLT3 [D835Y] in one patient each), while loss of FLT3 ‐ITD was observed in two patients. In efficacy analyses ( n = 15), CRc rate was 66.7% (95% confidence interval [CI], 38.4–88.2), ORR was 73.3% (44.9–92.2), and median OS was 13.6 months (5.4–not evaluable). Three patients (20.0%) received HSCT directly after quizartinib; in these patients, median RFS was 8.5 months (95% CI, 6.2–not evaluable). Grade ≥ 3 non‐hematologic AEs and grade 1 QT prolongation were each reported in three patients (20.0%). These data offer additional information on potential resistance mechanisms in patients with relapsed or refractory FLT3 ‐ITD–positive AML. Trial Registration: Japan Registry of Clinical Trials (jRCTs071200015).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePhenylurea CompoundsDrug Resistance, NeoplasmMutationBenzothiazolesProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedAgedAdultTreatment OutcomeJapanNeoplasm Recurrence, Local

Stichwörter der Autor:innen

FMS‐like tyrosine kinase 3acute myeloid leukemiadrug resistancenext‐generation sequencingquizartinib

Substanzen

quizartinibfms-Like Tyrosine Kinase 3Phenylurea CompoundsFLT3 protein, humanBenzothiazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
  • Division of Precision Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
  • Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
  • Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
  • Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Hematology, Saga Prefecture Medical Center Koseikan, Saga, Japan.

ORCID-Profile: Toshihiro Miyamoto, Yuho Najima, Koji Kato, Koji Nagafuji, Koichi Iwanaga

Förderung

  • Daiichi Sankyo Co., Ltd

Zitieren

APA

Semba, Y., Miyamoto, T., Kasahara, S., Kikushige, Y., Maeda, T., Yoshimoto, G., Ota, S., Saito, A., Najima, Y., Hosoi, H., Niiya, D., Kato, K., Nagafuji, K., Akasaka, T., Kamimura, T., Takita, A., Narahara, M., Toki, T., Iwanaga, K., …, & Akashi, K. (2026). Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML. Cancer Science, 117(11), 3108-3120. https://doi.org/10.1111/cas.70485

Vancouver

Semba Y, Miyamoto T, Kasahara S, Kikushige Y, Maeda T, Yoshimoto G, et al. Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML. Cancer Science. 2026;117(11):3108-3120. doi:10.1111/cas.70485

BibTeX
@article{Semba2026,
  author = {Semba, Yuichiro and Miyamoto, Toshihiro and Kasahara, Senji and Kikushige, Yoshikane and Maeda, Takahiro and Yoshimoto, Goichi and Ota, Shuichi and Saito, Akio and Najima, Yuho and Hosoi, Hiroki and Niiya, Daigo and Kato, Koji and Nagafuji, Koji and Akasaka, Takashi and Kamimura, Tomohiko and Takita, Atsushi and Narahara, Maiko and Toki, Tadashi and Iwanaga, Koichi and Yonemoto, Koji and Harada, Mine and Akashi, Koichi},
  title = {Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {11},
  pages = {3108--3120},
  doi = {10.1111/cas.70485}
}
Kostenlos starten →